Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Proteomics|March 19, 2013
Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discoverySimona Principe, Angela Bik-Yu Hui, Jeff Bruce, et al.
International Journal of Oncology|December 9, 2004
Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell linesYan-Yan Or, Angela Bik-Yu Hui, Ka-Ying Tam, et al.
International Journal of Oncology|February 12, 2002
Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridizationAngela Bik-Yu Hui, Kwok-Wai Lo, Peter M L Teo, et al.
Cancer Genetics and Cytogenetics|May 9, 2002
Genome-wide survey for chromosomal imbalances in ganglioglioma using comparative genomic hybridizationXiao Lu Yin, Angela Bik-Yu Hui, Jesse Chung-Sean Pang, et al.
Cancer Genetics and Cytogenetics|January 22, 2002
Genetic imbalances in pleomorphic xanthoastrocytoma detected by comparative genomic hybridization and literature reviewXiao-Lu Yin, Angela Bik-Yu Hui, Eleanore C Liong, et al.
Cancer Treatment and Research Communications|November 25, 2022
Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancerJacqueline V Aredo, Heather A Wakelee, Angela Bik-Yu Hui, et al.
Molecular Carcinogenesis|November 26, 2003
Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinomaAngela Bik-Yu Hui, Kwok-Wai Lo, Joseph Kwong, et al.
Nature Communications|December 24, 2016
Reprogramming the immunological microenvironment through radiation and targeting AxlTodd A Aguilera, Marjan Rafat, Laura Castellini, et al.
International Journal of Oncology|March 17, 2009
Progressive increase of genetic alteration in urinary bladder cancer by combined allelotyping analysis and comparative genomic hybridizationMichael W Y Chan, Angela Bik-Yu Hui, Sidney Kam-Hung Yip, et al.
JTO Clinical and Research Reports|December 3, 2024
Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLCJacqueline V Aredo, Heather A Wakelee, Kavitha J Ramchandran, et al.
Pageof 2